Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Regulatory Non-interventional Study to Monitor the Safety and Efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean Patients With Chronic Kidney Disease (CKD)

NCT06287073 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06287073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06287073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Regulatory Non-interventional Study to Monitor the Safety and Efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean Patients With Chronic Kidney Disease (CKD)
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
March 29, 2024
Completion date
April 30, 2025
Enrollment
299 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

kidney disease, chronic